<DOC>
	<DOCNO>NCT00203138</DOCNO>
	<brief_summary>Patients complete study TVP-1012/232 eligible enter extension study continue rasagiline therapy Parkinson 's disease ( PD ) . During study patient 's safety , tolerability rasagiline , effectiveness therapy monitor .</brief_summary>
	<brief_title>Safety , Tolerability , Effectiveness Rasagiline Mesylate Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>• Patients complete evaluation week 52 TVP 1012/232 protocol , continue rasagiline therapy warrant , opinion principal investigator • Patients suffer adverse effect probably drugrelated TVP1012/232 study</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>